Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesImmunitybio Inc

Immunitybio Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
6.6289 USD -2.01 ( 23.23%)
Last update at 2026-11-09T15:38:00Z
VOLUME
24949984
Market Cap
8627.07M

Momentum Score

…

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
6.36
Low
7.29
High
52 Week Price Range
1.95
Low
12.43
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

ImmunityBio is a clinical-stage immunotherapy company developing cytokine-based and cell-therapy treatments for cancer and infectious diseases. Long-term growth may be driven by clinical trial readouts, regulatory approvals, partnerships and commercialization of its biologic platforms. Investors may find potential upside attractive if pivotal data demonstrate durable clinical benefit.
Major risks include high clinical and regulatory failure risk, substantial cash burn and dilution from future financings, and execution challenges scaling manufacturing and commercialization.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
8.63
Dividend Yield
-
Revenue TTM
165.79M
Revenue Per Share
0.17
Gross Profit TTM
164.70M
Debt / Equity
-1.76
ROE
-
Net Debt
789.78M
ROCE
-54.32%
Diluted EPS TTM
-0.93

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -351.61M -413.64M -583.89M -417.29M -349.84M
Minority interest 0.07M 0.08M 0.74M -0.75M -3.06M
Net income -351.40M -413.56M -583.20M -417.32M -349.85M
Selling general administrative 150.00M 168.78M 122.72M 102.71M 135.26M
Gross profit 112.53M 14.74M -17.89M -23.95M 0.93M
Reconciled depreciation 15.53M 17.55M 19.17M 18.26M 14.24M
Ebit -239.08M -281.99M -361.36M -351.30M -330.28M
Ebitda -223.56M -264.43M -342.85M -343.98M -316.30M
Depreciation and amortization 15.53M 17.55M 18.51M 7.32M 13.98M
Non operating income net other - - - -2.47M -4.71M
Operating income -256.03M -344.18M -361.36M -351.30M -330.28M
Other operating expenses 369.31M 358.93M 361.99M 350.86M 331.21M
Interest expense 112.53M 131.66M 129.20M 63.52M 14.85M
Tax provision -0.14M 0.00M 0.03M 0.03M 0.01M
Interest income 2.69M 2.40M 2.00M 2.71M 0.84M
Net interest income -109.84M -151.93M -123.63M -60.81M -14.01M
Non recurring - - - 0.68M -
Income tax expense -0.14M 0.08M -0.04M 0.03M 0.01M
Total revenue 113.29M 14.74M 0.62M 0.24M 0.93M
Total operating expenses 368.56M 358.93M 343.47M 350.86M 331.21M
Cost of revenue 0.75M 17.55M 18.51M 24.19M -
Total other income expense net -95.58M -69.46M -222.53M -65.99M -19.56M
Net income from continuing ops -351.47M -413.64M -458.76M -417.32M -349.85M
Net income applicable to common shares - - - -416.57M -346.79M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 501.90M 382.93M 504.45M 362.36M 468.91M
Intangible assets 13.04M 15.02M 17.09M 20.00M 1.42M
Other current assets 28.53M 23.85M 24.45M 5.15M 15.90M
Total liab 1001.47M 871.06M 1090.39M 812.18M 712.82M
Total stockholder equity -499.57M -489.10M -586.99M -447.33M -242.17M
Deferred long term liab - - - - 0.16M
Other current liab 45.49M 40.75M 42.20M 45.29M 55.33M
Common stock 0.10M 0.09M 0.07M 0.04M 0.04M
Capital stock 0.10M 0.09M 0.07M 0.04M 0.04M
Retained earnings -3726.65M -3375.25M -2961.68M -2378.49M -1961.92M
Other liab - - - 22.03M 0.41M
Good will 0.91M 0.91M - - -
Other assets - - - 6.63M 6.38M
Cash 88.33M 143.43M 265.45M 104.64M 181.10M
Total current liabilities 61.75M 54.94M 58.28M 500.86M 369.00M
Current deferred revenue - 0.10M 0.10M - -
Net debt 789.78M 360.74M 618.22M 619.13M 464.56M
Short term debt 9.29M 7.47M 6.78M 434.55M 302.25M
Short long term debt - - - 431.90M 299.24M
Short long term debt total 878.12M 504.17M 883.68M 723.77M 645.66M
Other stockholder equity 3198.03M 2884.87M 2374.62M 1930.94M 1719.70M
Property plant equipment - - - 143.66M 82.86M
Total current assets 314.88M 184.59M 294.08M 140.58M 334.35M
Long term investments - 0.00M 0.89M 0.84M 0.82M
Net tangible assets - - - -467.33M -243.59M
Short term investments 154.48M 6.38M 1.01M 2.54M 136.01M
Net receivables 42.62M 2.65M 3.17M 1.89M 1.33M
Long term debt 477.09M 461.88M 681.54M 241.27M 306.35M
Inventory 0.91M 8.27M - 26.35M -
Accounts payable 6.98M 6.72M 9.20M 21.02M 11.42M
Noncontrolling interest in consolidated entity - - - -2.49M -1.74M
Accumulated other comprehensive income 28.96M 1.20M 0.01M 0.18M 0.00M
Common stock total equity - - - 0.04M 0.04M
Retained earnings total equity - - - -2378.49M -1961.92M
Non currrent assets other 15.04M 11.26M 2.49M 6.63M 7.20M
Non current assets total 187.02M 198.35M 210.37M 221.78M 134.56M
Capital lease obligations 40.98M 42.29M 45.19M 50.60M 40.08M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -145.55M -12.25M -51.61M 126.69M -71.82M
Change to liabilities - - - 12.10M 1.47M
Total cashflows from investing activities -149.80M -12.25M -30.47M 27.30M -84.89M
Net borrowings 2.86M -0.06M 258.62M 174.12M 338.50M
Total cash from financing activities 400.24M 281.63M 558.34M 233.61M 505.44M
Change to operating activities - - - -16.00M -15.39M
Net income -351.47M -413.64M -583.85M -417.32M -349.85M
Change in cash -54.48M -121.88M 160.82M -76.31M 146.19M
Begin period cash flow 143.91M 265.79M 104.97M 181.28M 35.09M
End period cash flow 89.43M 143.91M 265.79M 104.97M 181.28M
Total cash from operating activities -304.94M -391.24M -366.76M -337.51M -274.42M
Issuance of capital stock 400.56M 111.36M 161.17M 60.43M 164.53M
Depreciation 15.53M 17.55M 18.51M 18.26M 14.24M
Other cashflows from investing activities -149.80M -0.75M - -21.23M 20.50M
Change to inventory -6.33M -8.27M 0.00M - -
Change to account receivables -40.21M -2.36M 0.00M - -
Sale purchase of stock - - -3.44M 60.50M 171.43M
Other cashflows from financing activities -2.27M 73.38M -3.44M 173.24M 340.91M
Change to netincome - - - 29.00M 58.33M
Capital expenditures 3.85M 6.89M 30.58M 99.39M 33.56M
Cash flows other operating - - - 2.85M 1.40M
Cash and cash equivalents changes - - - -76.60M 146.14M
Change in working capital -54.33M -19.42M 3.83M -8.00M -19.11M
Stock based compensation 36.81M 34.43M 49.16M 40.18M 57.18M
Other non cash items 48.53M -10.15M 145.44M 29.38M 23.13M
Free cash flow -308.78M -398.12M -397.34M -436.90M -307.98M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IBRX
Immunitybio Inc		 -2.01
23.23%		 6.63 - 119.05 52.04 - 56.25 -8.99
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Immunitybio Inc

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

3530 John Hopkins Court, San Diego, CA, United States, 92121

844 696 5235

https://immunitybio.com

684

Name Title Year Born
Dr. Patrick Soon-Shiong FACS, FRCS (C), M.Sc. Exec. Chairman, Global Chief Scientific & Medical Officer 1953
Mr. Richard Gerald Adcock Pres, CEO & Director 1969
Mr. David C. Sachs CFO, Principal Financial Officer & Principal Accounting Officer 1978
Dr. Leonard S. Sender M.D. Chief Operating Officer NA
Mr. Jason R. Liljestrom Gen. Counsel & Corp. Sec. 1983
Ms. Sarah Singleton Chief Communications Officer NA
Dr. Sandeep K. Reddy M.D. Chief Medical Officer NA
Dr. Barry J. Simon M.D. Chief Corp. Affairs Officer & Director 1965
Dr. Hans Georg Klingemann M.D., Ph.D. Chief Science Officer of Cellular 1950
Ms. Helen Luu Chief Commercial Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.19%

  • Communication Services

    -0.04%

  • Consumer Cyclical

    +0.27%

  • Consumer Defensive

    -0.21%

  • Energy

    +1.16%

  • Financial Services

    +0.81%

  • Healthcare

    +0.03%

  • Industrials

    +1.64%

  • Real Estate

    +0.06%

  • Technology

    +0.38%

  • Utilities

    +0.68%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…